Stage 4 Non Small Cell Lung Cancer Life Expectancy

Stage 4 non small cell lung cancer life expectancy - Every year, he diagnosed more than 220 000 Americans. There are two main types of lung cancer: small Cells (SCLC) and non-small cells (NSCLC). NSCLC is the most common type of lung cancer, affecting 85 to 90 percent of all patients with lung cancer. It is prone to be less aggressive than the SCLC, which means that the treatments are often more successful.

Although smoking is one of the biggest risk factors for lung cancer, NSCLC can be caused by other environmental factors. These are air pollutants, radon, and arsenic that are found in drinking water. Family history also puts you at a higher risk. Stage 4 non small cell lung cancer life expectancy - But if cancer is detected and treated early, your chances of living a healthy and normal life are optimistic.

Lung cancer affects older people most. This is most often diagnosed among people aged 65 to 74 years. at 2011. In the year 82% of patients with lung cancer were 60 years of age or older. 1-2 the majority of patients diagnosed with lung cancer were identified with stage III or stage IV diseases. Age is not a significant factor in predicting the overall survival of lung cancer; Setting this disease is more relevant to the survival rate. See Also: Stage 4 Lung Cancer Life Expectancy With Treatment.

For most patients, age does not affect the way in which a person responds to treatment. However, treatment options can be adapted to elderly patients, depending on their overall health. Some studies show that they have other health conditions or comorbidity negatively affect the patient's prognosis, regardless of patient's age. This means that other health conditions could have a greater impact on survival than age.

Stage 4 Non Small Cell Lung Cancer Treatment

One study studied the medical history of elderly patients to understand how age and other health conditions affect the choices of treatment and survival. Stage 4 non small cell lung cancer life expectancy - Patients had non-small cell lung cancer (NSCLC) and an average age of 62.7 years. Approximately 57% of patients have other diseases, chronic obstructive pulmonary disease (COPD) and cardiovascular disease.

Researchers found that the presence of other health conditions affects recommendations for treatment and has at least two other health conditions that have negatively influenced survival in advanced stages of lung cancer, regardless of the age of the patient. This means that other health conditions have a greater impact on survival than age. Research has also shown that the age of patients should not be a factor in whether chemotherapy is the right choice because treatment increases survival among younger and elderly patients. However, the study concluded that comorbidity can affect whether chemotherapy is a real treatment for individual patients. See also: Lung Cancer Life Expectancy Stage 2.

Another study conducted in Holland, which was presented on 14. World Congress of Lung cancer in 2011. Demonstrated that the survival of elderly patients with FAZ and NSCLC was significantly increased by stereotactic ablation radiotherapy, also known as stereotactical radiotherapy of the body (SABR). Conventional radiation therapy is usually not considered a beneficial option for elderly patients due to daycare for 6-7 weeks, potential patient weaknesses and high recurrence rates (cancer return). With the SABR, high-pressure radiation is focused on tumors from different angles for 3-5 visits, while reducing the exposure of healthy body parts. This study shows that elderly patients treated with SABR have an increase in the survival rate of almost 10 months.

Italian review article that assesses the use of chemotherapy and targeted therapy (those targeting specific genetic mutations found in some tumors of lung cancer) have also found that comorbid elderly patients make them less capable of tolerating Medical care compared to younger patients. However, elderly people also have the risk of treatment (receiving less aggressive cancer treatment), resulting in bad survival rates. This study notes that elderly patients submit well-targeted therapy, especially EGFR Tarceva inhibitors (erlotinib) and Iressa (gefitinib).